SAB Biotherapeutics, Inc.
SABSBiotechnology
$3.35+3.72%As of Oct 30vs prior close
- Market cap
- $304.8M
- P/E (TTM)
- 15.2×
- From 52W high
- −27.02%
- EPS (YE25)
- -$0.79
- Revenue (YE25)
- $0
- Dividend yield
- 0.00%
Nomior Score
27
Steady ProfileBottom 12% of the scored universe
Growth36
Quality35
Value42
Momentum41
Resilience33
Growth
$0revenue, YE25
YE20 $55.2MYE25 $0
Connections
Revenue to profitQ4 YE24
The operating loss was 8726% of revenue, wider by 2538 pts on a year.
Who owns it
2funds